Optimal duration of anticoagulation

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Theme Issue
Venous thromboembolism

Issue: 2015: 113/6 (June) pp. 1159–1382
Pages: 1210-1215
Ahead of Print: 2014-08-14

Optimal duration of anticoagulation

Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests

Theme Issue Article for Theme Issue "Venous Thromboembolism"

P. Prandoni (1), S. Barbar (1), M. Milan (1), E. Campello (1), L. Spiezia (1), C. Piovella (1), R. Pesavento (1)

(1) Department of Medicine, Vascular Medicine Unit, University of Padua, Italy


pulmonary embolism, Deep venous thrombosis, thrombophilia, venous thromboembolism, Ultrasonography, anticoagulation, residual thrombosis


Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after a first episode is consistently around 30%. This risk is higher in patients with unprovoked than in those with (transient) provoked VTE, and among the latter in patients with medical than in those with surgical risk factors. Baseline parameters that have been found to be related to the risk of recurrent VTE are the proximal location of deep-vein thrombosis, obesity, old age, male sex and non-0 blood group, whereas the role of inherited thrombophilia is controversial. The persistence of residual vein thrombosis at ultrasound assessment has consistently been shown to increase the risk, as do persistently high values of D-dimer and the early development of the post-thrombotic syndrome. Although the latest international guidelines suggest indefinite anticoagulation for most patients with the first episode of unprovoked VTE, strategies that incorporate the assessment of residual vein thrombosis and D-dimer have the potential to identify subjects in whom anticoagulation can be safely discontinued. Moreover, new opportunities are offered by a few emerging anti-Xa and anti-IIa oral compounds, which are likely to induce fewer haemorrhagic complications than vitamin K antagonists while preserving the same effectiveness; and by low-dose aspirin, which has the potential to prevent the occurrence of both venous and arterial thrombotic events.

You may also be interested in...


P. Prandoni (1)

Phlebologie 2017 46 5: 288-291

H. Leon Daneschvar 1, Ali Seddighzadeh 1, Gregory Piazza 2, Samuel Z. Goldhaber1

Thromb Haemost 2008 99 6: 1035-1039

Cihan Ay1,*, Lea V. Jungbauer2,*, Alexandra Kaider 3, Silvia Koder 1, Simon Panzer 4, Ingrid Pabinger 1, Christine Mannhalter2

Thromb Haemost 2008 99 5: 899-904